AU2001236623A1 - Hydantoin c-proteinase inhibitors - Google Patents

Hydantoin c-proteinase inhibitors

Info

Publication number
AU2001236623A1
AU2001236623A1 AU2001236623A AU3662301A AU2001236623A1 AU 2001236623 A1 AU2001236623 A1 AU 2001236623A1 AU 2001236623 A AU2001236623 A AU 2001236623A AU 3662301 A AU3662301 A AU 3662301A AU 2001236623 A1 AU2001236623 A1 AU 2001236623A1
Authority
AU
Australia
Prior art keywords
hydantoin
proteinase inhibitors
proteinase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001236623A
Inventor
Udo Bauer
Wen-Bin Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen Inc
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of AU2001236623A1 publication Critical patent/AU2001236623A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001236623A 2000-02-04 2001-02-02 Hydantoin c-proteinase inhibitors Abandoned AU2001236623A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/497,946 US6462063B1 (en) 2000-02-04 2000-02-04 C-proteinase inhibitors
US09497946 2000-02-04
PCT/US2001/003410 WO2001056996A1 (en) 2000-02-04 2001-02-02 Hydantoin c-proteinase inhibitors

Publications (1)

Publication Number Publication Date
AU2001236623A1 true AU2001236623A1 (en) 2001-08-14

Family

ID=23978983

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001236623A Abandoned AU2001236623A1 (en) 2000-02-04 2001-02-02 Hydantoin c-proteinase inhibitors

Country Status (3)

Country Link
US (1) US6462063B1 (en)
AU (1) AU2001236623A1 (en)
WO (1) WO2001056996A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001261519A1 (en) * 2000-05-12 2001-11-26 Fibrogen, Inc. Methods of affecting laminin 5 processing
JP4711523B2 (en) * 2001-02-13 2011-06-29 日本臓器製薬株式会社 Hypoalbuminemia improving agent
US7354933B2 (en) 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
DOP2005000123A (en) 2004-07-02 2011-07-15 Merck Sharp & Dohme CETP INHIBITORS
JP5186384B2 (en) 2005-12-14 2013-04-17 メディヴィル・アクチボラグ (2,5-Dioxoimidazolidin-1-yl) -N-hydroxy-acetamide as a metalloproteinase inhibitor
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
US20090163494A1 (en) * 2007-12-19 2009-06-25 Pao-Chiung Hong Protein kinase inhibitors
WO2009085040A1 (en) * 2007-12-27 2009-07-09 Dcb-Usa Llc Protein kinase inhibitors
AU2009259136B2 (en) 2008-06-09 2014-09-25 Cyclacel Limited Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine
TW201031650A (en) 2008-12-02 2010-09-01 Organon Nv 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione
TW201031649A (en) 2008-12-02 2010-09-01 Organon Nv 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
EP2696878B1 (en) 2011-04-14 2019-07-10 Cyclacel Limited Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
EP2664616A1 (en) * 2012-05-15 2013-11-20 Vivalis Hydantoin and thiohydantoin derivatives as antiviral drugs
CN110143925B (en) * 2019-06-05 2022-10-25 山东大学 Hydantoin hydroxamic acid histone deacetylase 6 subtype selective inhibitor, and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0640594A1 (en) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
GB9411088D0 (en) 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
WO1997005865A1 (en) 1995-08-08 1997-02-20 Fibrogen, Inc. C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen
BR9807678A (en) 1997-02-11 2000-02-15 Pfizer Derivatives of arylsulfonyl hydroxamic acids

Also Published As

Publication number Publication date
US6462063B1 (en) 2002-10-08
WO2001056996A1 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
AU2001258771A1 (en) -secretase inhibitors
AU2001237041A1 (en) Kinase inhibitors
HK1091492A1 (en) Hydantoin derivatives as mmp inhibitors
AU2001234128A1 (en) Novel imidazoline compounds
AU2001296961A1 (en) 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
AU2002250394A1 (en) Rho-kinase inhibitors
AU2002245709A1 (en) Rho-kinase inhibitors
AU2002219555A1 (en) VLA-4 Inhibitors
AU4882101A (en) Mmp-12 inhibitors
AU2002220241A1 (en) Parb inhibitors
AU2002211663A1 (en) Nf-$g(k)b inhibitors
AU2001258784A1 (en) Tyrosine phosphatase inhibitors
AU2001285750A1 (en) Urokinase inhibitors
AU2002230385A1 (en) Peptide deformylase inhibitors
AU2001247589A1 (en) Non-amidine containing protease inhibitors
AU2001236623A1 (en) Hydantoin c-proteinase inhibitors
AU2001236052A1 (en) Urease inhibitors
AU2002211662A1 (en) Nf-kappab inhibitors
AU2001259354A1 (en) Phosphate transport inhibitors
AU2002222627A1 (en) Tak1 inhibitors
AUPP982399A0 (en) Mmp inhibitor
AU2002224550A1 (en) Corrosion inhibitors
AU2002249809A1 (en) Potassium channel inhibitors
AU3235100A (en) Prothease inhibitors
GB0030284D0 (en) Enzyme inhibitors